Mirum Pharmaceuticals (NASDAQ:MIRM) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM) in a report issued on Friday morning, Benzinga reports. The brokerage currently has a $66.00 price objective on the stock.

Several other equities research analysts also recently weighed in on MIRM. JMP Securities upped their price target on Mirum Pharmaceuticals from $66.00 to $68.00 and gave the stock a market outperform rating in a report on Tuesday, June 18th. Baird R W raised Mirum Pharmaceuticals to a strong-buy rating in a research report on Monday, June 17th. SVB Leerink lowered their price objective on Mirum Pharmaceuticals from $44.00 to $43.00 and set an outperform rating for the company in a research report on Monday, March 18th. Stifel Nicolaus reaffirmed a buy rating and set a $48.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, June 17th. Finally, Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $34.00 to $39.00 and gave the stock an outperform rating in a research report on Monday, June 17th. Ten analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $53.64.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $34.19 on Friday. Mirum Pharmaceuticals has a 52 week low of $23.14 and a 52 week high of $35.56. The business’s fifty day simple moving average is $26.62 and its 200-day simple moving average is $27.22. The firm has a market cap of $1.61 billion, a PE ratio of -9.22 and a beta of 1.10. The company has a quick ratio of 3.47, a current ratio of 3.68 and a debt-to-equity ratio of 1.31.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.14). The firm had revenue of $69.22 million during the quarter, compared to analysts’ expectations of $69.71 million. Mirum Pharmaceuticals had a negative net margin of 69.67% and a negative return on equity of 56.46%. Equities analysts forecast that Mirum Pharmaceuticals will post -1.66 earnings per share for the current year.

Insider Transactions at Mirum Pharmaceuticals

In other news, insider Pamela Vig sold 30,559 shares of the business’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $34.00, for a total transaction of $1,039,006.00. Following the sale, the insider now owns 27,406 shares of the company’s stock, valued at approximately $931,804. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Saira Ramasastry sold 5,000 shares of the company’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $25.68, for a total transaction of $128,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Pamela Vig sold 30,559 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $34.00, for a total value of $1,039,006.00. Following the completion of the sale, the insider now owns 27,406 shares of the company’s stock, valued at $931,804. The disclosure for this sale can be found here. Corporate insiders own 22.87% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

Several large investors have recently added to or reduced their stakes in MIRM. New York State Common Retirement Fund grew its stake in shares of Mirum Pharmaceuticals by 0.4% during the fourth quarter. New York State Common Retirement Fund now owns 222,864 shares of the company’s stock valued at $6,579,000 after acquiring an additional 918 shares in the last quarter. Golden State Equity Partners lifted its position in shares of Mirum Pharmaceuticals by 5.3% during the fourth quarter. Golden State Equity Partners now owns 18,930 shares of the company’s stock worth $559,000 after purchasing an additional 950 shares during the last quarter. Wetzel Investment Advisors Inc. lifted its position in shares of Mirum Pharmaceuticals by 71.4% during the first quarter. Wetzel Investment Advisors Inc. now owns 2,400 shares of the company’s stock worth $57,000 after purchasing an additional 1,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Mirum Pharmaceuticals by 7.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 18,641 shares of the company’s stock worth $448,000 after purchasing an additional 1,246 shares during the last quarter. Finally, AJOVista LLC bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth about $40,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.